nmCRPC VL

The Treatment of Non-Metastatic Castration-Resistant Prostate Cancer: "Pros" Presentation - Maha Hussain

Details
Maha Hussain presents during the Management of Castration-Resistant Prostate Cancer (CRPC) debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Hussain focuses on the "pros" of treating men with non-metastatic CRPC while revisiting the transformation of the field back to 2011 where stood an area of unmet need. The past 18 months have seen the reporting and FDA approval of...

The "Cons" of Treating nmCRPC - Important Considerations to Take into Account Presentation - Celestia Higano

Details
Celestia (Tia) Higano followed Maha Hussain's presentation on the "pros" of the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) with the opposing side of the debate at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Higano focuses on the "cons" of treating men with nmCRPC and highlights an extensively covered topic at the meeting, the emergence and upd...

Darolutamide Treated Patients Maintained Quality of Life in ARAMIS Trial - Fred Saad

Details
Fred Saad joins Alicia Morgans to discuss the quality of life data from the ARAMIS trial. The data suggest that adding darolutamide (systemic therapy) to ADT compared to ADT alone improves quality of life in the patients, and these include bowel and urinary symptom benefits along with the skeletal outcomes and quality-of-life measures. The ARAMIS study suggests that androgen receptor antagonist da...

ARAMIS Trial in Prostate Cancer: Impact of Darolutamide on Pain and Quality of Life - Karim Fizazi

Details
Karim Fizazi and Alicia Morgans discuss a follow-up on the quality of life parameters evaluated in the ARAMIS trial. Darolutamide was also associated with benefits with regard to all secondary end points, including overall survival, time to pain progression, time to cytotoxic chemotherapy, and time to a symptomatic skeletal-related event. The incidence of adverse events that occurred or worsened d...

Darolutamide Demonstrates Efficacy and Safety in Men with nmCRPC - Neeraj Agarwal

Details
Petros Grivas discussed Neeraj Agarwal's insights about the latest prostate cancer study results that will impact patient care as presented at ASCO GU 2019. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer. Darolutamide is a structurally unique androgen-receptor antagonist that is under develop...

ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC - Karim Fizazi

Details
Karim Fizazi discusses the efficacy and safety of darolutamide with Alicia Morgans. The ARAMIS trial evaluated the efficacy of darolutamide for delaying metastasis and death in men with nonmetastatic, castration-resistant prostate cancer (nmCRPC). Darolutamide is a structurally unique androgen-receptor antagonist that is under development for the treatment of prostate cancer. In total, 1509 patien...

Delaying Disease Progression in Early Nonmetastatic CRPC Treatment - Fred Saad

Details
In this interview, Fred Saad reviews current and new agents showing benefit in the nonmetastatic castrate-resistant prostate cancer (nmCRPC) space and where the treatment paradigm stands in 2019 since data release in 2018. In addition, Fred makes the case for earlier treatment in nmCRPC patients and how targeting the androgen receptor is extremely effective which leads to better survival rates and...

Abiraterone Acetate for nmCRPC, The Forgotten Dance Partner? - Zach Klaassen and Chris Wallis

Details
Zach Klaassen and Chris Wallis discuss a jointly published paper that was published in Jama Oncology, November, titled, “Abiraterone Acetate for Nonmetastatic Castration-Resistant Prostate Cancer, The Forgotten Dance Partner?” They reference recent trials in this space and discuss cost and other variables to consider when making a therapeutic decision. Biographies: Zachary Klaassen, MD, MSc, Urolo...

IMAAGEN Trial: A Look into the Non-Metastatic Prostate Cancer Space - Charles Ryan

Details
(Length of Discussion: 20 min) Alicia Morgans and Charles Ryan have a dialogue on the study design, results and conclusions from the IMAAGEN trial in the non-metastatic prostate cancer space. The IMAAGEN trial evaluated the use of abiraterone acetate (1,000 mg) plus prednisone (5 mg) in patients with high risk, nonmetastatic, castration resistant prostate cancer. Biographies: Charles J. Ryan, MD A...

Comparison Between Surgery and Radiotherapy in the Treatment of Non-Metastatic Prostate Cancer- Christopher Wallis

Details
(Length of Presentation: 8 minutes) Christopher Wallis presents observational data from a large, population-based matched cohort demonstrating an association between treatment with radiotherapy vs radical prostatectomy and non-prostate cancer mortality. This controversial topic in urologic oncology is a usual subject of interest with respect to comparative effectiveness studies. In observational s...
email news signup